메뉴 건너뛰기




Volumn 58, Issue 8, 2001, Pages 671-683

Angiotensin II-receptor blockers: Clinical relevance and therapeutic role

Author keywords

Angiotensin antagonists; Angiotensin converting enzyme inhibitors; Clinical studies; Diabetic nephropathies; Drug comparisons; Heart failure; Hypertension; Toxicity

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPROSARTAN; IRBESARTAN; LOSARTAN POTASSIUM; TELMISARTAN; VALSARTAN;

EID: 0035871519     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/58.8.671     Document Type: Review
Times cited : (48)

References (121)
  • 1
    • 0026762669 scopus 로고
    • Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology
    • Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med. 1992; 117:234-42.
    • (1992) Ann Intern Med , vol.117 , pp. 234-242
    • Israili, Z.H.1    Hall, W.D.2
  • 2
    • 0025950044 scopus 로고
    • Prevalence of persistent cough during long-term enalapril treatment: Controlled study versus nifedipine
    • Yeo WW, Foster G, Ramsay LE. Prevalence of persistent cough during long-term enalapril treatment: controlled study versus nifedipine. Q J Med. 1991; 80:763-70.
    • (1991) Q J Med , vol.80 , pp. 763-770
    • Yeo, W.W.1    Foster, G.2    Ramsay, L.E.3
  • 3
    • 0029910150 scopus 로고    scopus 로고
    • Use of baclofen to suppress cough induced by angiotensin-converting enzyme inhibitors
    • Dicpinigaitis PV. Use of baclofen to suppress cough induced by angiotensin-converting enzyme inhibitors. Ann Pharmacother. 1996; 30:1242-5.
    • (1996) Ann Pharmacother , vol.30 , pp. 1242-1245
    • Dicpinigaitis, P.V.1
  • 4
    • 0031765704 scopus 로고    scopus 로고
    • ACE inhibitor- Versus angiotensin II blocker-induced cough and angioedema
    • Pylypchuk GB. ACE inhibitor- versus angiotensin II blocker-induced cough and angioedema. Ann Pharmacother. 1998; 32:1060-6.
    • (1998) Ann Pharmacother , vol.32 , pp. 1060-1066
    • Pylypchuk, G.B.1
  • 5
    • 0004106150 scopus 로고    scopus 로고
    • Wayne, PA: Astra Pharmaceuticals
    • Atacand package insert. Wayne, PA: Astra Pharmaceuticals; 1998.
    • (1998) Atacand Package Insert
  • 6
    • 0004243460 scopus 로고    scopus 로고
    • Princeton, NJ: Bristol-Myers Squibb Company
    • Avapro package insert. Princeton, NJ: Bristol-Myers Squibb Company; 1998.
    • (1998) Avapro Package Insert
  • 7
    • 0003782943 scopus 로고    scopus 로고
    • West Point, PA: Merck & Co.;
    • Cozaar package insert. West Point, PA: Merck & Co.; 1999.
    • (1999) Cozaar Package Insert
  • 8
    • 0003878094 scopus 로고    scopus 로고
    • East Hanover, NJ: Novartis Pharmaceuticals
    • Diovan package insert. East Hanover, NJ: Novartis Pharmaceuticals; 1998.
    • (1998) Diovan Package Insert
  • 9
    • 0003496154 scopus 로고    scopus 로고
    • Buffalo Grove, IL: Solvay Pharmaceuticals
    • Teveten package insert. Buffalo Grove, IL: Solvay Pharmaceuticals; 1999.
    • (1999) Teveten Package Insert
  • 10
    • 0004327954 scopus 로고    scopus 로고
    • Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals
    • Micardis package insert. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals; 1999.
    • (1999) Micardis Package Insert
  • 12
    • 0028097788 scopus 로고
    • Angiotensin converting enzyme inhibitor modulates glomerular function and structure by distinct mechanisms
    • Tanaka R, Kon V, Yoshioka T et al. Angiotensin converting enzyme inhibitor modulates glomerular function and structure by distinct mechanisms. Kidney Int. 1994; 45:537-43.
    • (1994) Kidney Int , vol.45 , pp. 537-543
    • Tanaka, R.1    Kon, V.2    Yoshioka, T.3
  • 13
    • 0030902115 scopus 로고    scopus 로고
    • Randomised trial of losartan versus captopril in patients over 65 with heart failure
    • Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure. Lancet. 1997; 349:747-52.
    • (1997) Lancet , vol.349 , pp. 747-752
    • Pitt, B.1    Segal, R.2    Martinez, F.A.3
  • 14
    • 0027529918 scopus 로고
    • Angiotensin-converting enzyme inhibition does not suppress plasma angiotensin II increase during exercise in humans
    • Aldigier JC, Huang H, Dalmay F et al. Angiotensin-converting enzyme inhibition does not suppress plasma angiotensin II increase during exercise in humans. J Cardiovasc Pharmacol. 1993; 21:289-95.
    • (1993) J Cardiovasc Pharmacol , vol.21 , pp. 289-295
    • Aldigier, J.C.1    Huang, H.2    Dalmay, F.3
  • 15
    • 0028258564 scopus 로고
    • Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor
    • Rousseau MF, Konstam MA, Benedict CR et al. Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor. Am J Cardiol. 1994; 73:488-93.
    • (1994) Am J Cardiol , vol.73 , pp. 488-493
    • Rousseau, M.F.1    Konstam, M.A.2    Benedict, C.R.3
  • 16
    • 0027538401 scopus 로고
    • Heterogeneity of angiotensin synthetic pathways and receptor subtypes: Physiological and pharmacological implications
    • Dzau VJ, Sasamura H, Hein L. Heterogeneity of angiotensin synthetic pathways and receptor subtypes: physiological and pharmacological implications. J Hypertens Suppl. 1993; 11:S13-8.
    • (1993) J Hypertens Suppl , vol.11
    • Dzau, V.J.1    Sasamura, H.2    Hein, L.3
  • 17
    • 0033341628 scopus 로고    scopus 로고
    • Practical considerations of the pharmacology of angiotensin receptor blockers
    • McConnaughey MM, McConnaughey JS, Ingenito AJ. Practical considerations of the pharmacology of angiotensin receptor blockers. J Clin Pharmacol. 1999; 39:547-59.
    • (1999) J Clin Pharmacol , vol.39 , pp. 547-559
    • McConnaughey, M.M.1    McConnaughey, J.S.2    Ingenito, A.J.3
  • 18
    • 0027162040 scopus 로고
    • Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects
    • Burnier M, Rutschmann B, Nussberger J et al. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension. 1993; 22:339-47.
    • (1993) Hypertension , vol.22 , pp. 339-347
    • Burnier, M.1    Rutschmann, B.2    Nussberger, J.3
  • 19
    • 0026527261 scopus 로고
    • Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects
    • Nakashima M, Uematsu T, Kosuge K et al. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol. 1992; 42:333-5.
    • (1992) Eur J Clin Pharmacol , vol.42 , pp. 333-335
    • Nakashima, M.1    Uematsu, T.2    Kosuge, K.3
  • 20
    • 0029061433 scopus 로고
    • Effects of losartan on a background of hydrochlorothiazide in patients with hypertension
    • Soffer BA, Wright JT Jr, Pratt JH et al. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension. 1995; 26:112-7.
    • (1995) Hypertension , vol.26 , pp. 112-117
    • Soffer, B.A.1    Wright Jr., J.T.2    Pratt, J.H.3
  • 21
    • 0032558158 scopus 로고    scopus 로고
    • Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients
    • Minghelli G, Seydoux C, Goy JJ et al. Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients. Transplantation. 1998; 66:268-71.
    • (1998) Transplantation , vol.66 , pp. 268-271
    • Minghelli, G.1    Seydoux, C.2    Goy, J.J.3
  • 22
    • 0032578295 scopus 로고    scopus 로고
    • Uric acid as an independent risk factor in the treatment of hypertension
    • Ward HJ. Uric acid as an independent risk factor in the treatment of hypertension. Lancet. 1998; 352:670-1.
    • (1998) Lancet , vol.352 , pp. 670-671
    • Ward, H.J.1
  • 23
    • 0033005975 scopus 로고    scopus 로고
    • Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease
    • Johnson RJ, Kivlighn SD, Kim YG et al. Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. Am J Kidney Dis. 1999; 33:225-34.
    • (1999) Am J Kidney Dis , vol.33 , pp. 225-234
    • Johnson, R.J.1    Kivlighn, S.D.2    Kim, Y.G.3
  • 24
    • 0032722880 scopus 로고    scopus 로고
    • Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia
    • Shahinfar S, Simpson RL, Carides AD et al. Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. Kidney Int. 1999; 56:1879-85.
    • (1999) Kidney Int , vol.56 , pp. 1879-1885
    • Shahinfar, S.1    Simpson, R.L.2    Carides, A.D.3
  • 25
    • 0027469656 scopus 로고
    • Blood pressure, systolic and diastolic, and cardiovascular risks. US population data
    • Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med. 1993; 153:598-615.
    • (1993) Arch Intern Med , vol.153 , pp. 598-615
    • Stamler, J.1    Stamler, R.2    Neaton, J.D.3
  • 26
    • 0030750293 scopus 로고    scopus 로고
    • Valsartan. A review of its pharmacology and therapeutic use in essential hypertension
    • Markham A, Goa KL. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs. 1997; 54:299-311.
    • (1997) Drugs , vol.54 , pp. 299-311
    • Markham, A.1    Goa, K.L.2
  • 27
    • 0030694110 scopus 로고    scopus 로고
    • Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension
    • Gillis JC, Markham A. Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs. 1997; 54:885-902.
    • (1997) Drugs , vol.54 , pp. 885-902
    • Gillis, J.C.1    Markham, A.2
  • 28
    • 0030722238 scopus 로고    scopus 로고
    • Candesartan cilexetil: A new, long-acting, effective angiotensin II type 1 receptor blocker
    • Sever P. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker. J Hum Hypertens. 1997; 11(suppl 2):S91-5.
    • (1997) J Hum Hypertens , vol.11 , Issue.2 SUPPL.
    • Sever, P.1
  • 30
    • 0032923579 scopus 로고    scopus 로고
    • Clinical efficacy of eprosartan
    • Weber M. Clinical efficacy of eprosartan. Pharmacotherapy. 1999; 19:95S-101S.
    • (1999) Pharmacotherapy , vol.19
    • Weber, M.1
  • 31
    • 0031882729 scopus 로고    scopus 로고
    • The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan
    • Andersson OK, Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press. 1998; 7:53-9.
    • (1998) Blood Press , vol.7 , pp. 53-59
    • Andersson, O.K.1    Neldam, S.2
  • 32
    • 0031800774 scopus 로고    scopus 로고
    • Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators
    • Kassler-Taub K, Littlejohn T, Elliott W et al. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators. Am J Hypertens. 1998; 11:445-53.
    • (1998) Am J Hypertens , vol.11 , pp. 445-453
    • Kassler-Taub, K.1    Littlejohn, T.2    Elliott, W.3
  • 33
    • 0031901366 scopus 로고    scopus 로고
    • An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Irbesartan/Losartan Study Investigators
    • Oparil S, Guthrie R, Lewin AJ et al. An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Irbesartan/Losartan Study Investigators. Clin Ther. 1998; 20:398-409.
    • (1998) Clin Ther , vol.20 , pp. 398-409
    • Oparil, S.1    Guthrie, R.2    Lewin, A.J.3
  • 34
    • 0034030466 scopus 로고    scopus 로고
    • Angiotensin II antagonists for hypertension: Are there differences in efficacy?
    • Conlin PR, Spence JD, Williams B et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens. 2000; 13:418-26.
    • (2000) Am J Hypertens , vol.13 , pp. 418-426
    • Conlin, P.R.1    Spence, J.D.2    Williams, B.3
  • 35
    • 0033034404 scopus 로고    scopus 로고
    • Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial
    • Hansson L, Lindholm LH, Niskanen L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999; 353:611-6.
    • (1999) Lancet , vol.353 , pp. 611-616
    • Hansson, L.1    Lindholm, L.H.2    Niskanen, L.3
  • 36
    • 0032511601 scopus 로고    scopus 로고
    • Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
    • UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998; 317:713-20.
    • (1998) BMJ , vol.317 , pp. 713-720
  • 37
    • 0031944128 scopus 로고    scopus 로고
    • Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM
    • Tatti P, Pahor M, Byington RP et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998; 21:597-603.
    • (1998) Diabetes Care , vol.21 , pp. 597-603
    • Tatti, P.1    Pahor, M.2    Byington, R.P.3
  • 38
    • 0032485350 scopus 로고    scopus 로고
    • The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension
    • Estacio RO, Jeffers BW, Hiatt WR et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998; 338:645-52.
    • (1998) N Engl J Med , vol.338 , pp. 645-652
    • Estacio, R.O.1    Jeffers, B.W.2    Hiatt, W.R.3
  • 39
    • 0028848537 scopus 로고
    • A 12-month comparison of ACE inhibitor and CA antagonist therapy in mild to moderate essential hypertension - The GLANT study
    • Study Group on Long-term Antihypertensive Therapy. A 12-month comparison of ACE inhibitor and CA antagonist therapy in mild to moderate essential hypertension - the GLANT study. Hypertens Res. 1995; 18:235-44.
    • (1995) Hypertens Res , vol.18 , pp. 235-244
  • 40
    • 0034688194 scopus 로고    scopus 로고
    • Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients
    • Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med. 2000; 342:145-53.
    • (2000) N Engl J Med , vol.342 , pp. 145-153
  • 41
    • 0032436072 scopus 로고    scopus 로고
    • Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy
    • Benz JR, Black HR, Graff A et al. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens. 1998; 12:861-6.
    • (1998) J Hum Hypertens , vol.12 , pp. 861-866
    • Benz, J.R.1    Black, H.R.2    Graff, A.3
  • 42
    • 0028942349 scopus 로고
    • Blood pressure effects of the angiotensin II receptor blocker, losartan
    • Weber MA, Byyny RL, Pratt JH et al. Blood pressure effects of the angiotensin II receptor blocker, losartan. Arch Intern Med. 1995; 155:405-11.
    • (1995) Arch Intern Med , vol.155 , pp. 405-411
    • Weber, M.A.1    Byyny, R.L.2    Pratt, J.H.3
  • 43
    • 0030040951 scopus 로고    scopus 로고
    • Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components
    • MacKay JH, Arcuri KE, Goldberg AI et al. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med. 1996; 156:278-85.
    • (1996) Arch Intern Med , vol.156 , pp. 278-285
    • MacKay, J.H.1    Arcuri, K.E.2    Goldberg, A.I.3
  • 44
    • 0028874530 scopus 로고
    • Losartan potassium as initial therapy in patients with severe hypertension
    • Dunlay MC, Fitzpatrick V, Chrysant S et al. Losartan potassium as initial therapy in patients with severe hypertension. J Hum Hypertens. 1995; 9:861-7.
    • (1995) J Hum Hypertens , vol.9 , pp. 861-867
    • Dunlay, M.C.1    Fitzpatrick, V.2    Chrysant, S.3
  • 45
  • 46
    • 0028865295 scopus 로고
    • Role of angiotensin II in blood pressure regulation and in the pathophysiology of cardiovascular disorders
    • Fyhrquist F, Metsarinne K, Tikkanen I. Role of angiotensin II in blood pressure regulation and in the pathophysiology of cardiovascular disorders. J Hum Hypertens. 1995;9(suppl 5):S19-24.
    • (1995) J Hum Hypertens , vol.9 , Issue.5 SUPPL.
    • Fyhrquist, F.1    Metsarinne, K.2    Tikkanen, I.3
  • 47
    • 0021863924 scopus 로고
    • Global cardiac remodeling after acute myocardial infarction: A study in the rat model
    • Weisman HF, Bush DE, Mannisi JA et al. Global cardiac remodeling after acute myocardial infarction: a study in the rat model. J Am Coll Cardiol. 1985; 5:1355-62.
    • (1985) J Am Coll Cardiol , vol.5 , pp. 1355-1362
    • Weisman, H.F.1    Bush, D.E.2    Mannisi, J.A.3
  • 48
    • 0025978369 scopus 로고
    • Cellular basis of chronic ventricular remodeling after myocardial infarction in rats
    • Olivetti G, Capasso JM, Meggs LG et al. Cellular basis of chronic ventricular remodeling after myocardial infarction in rats. Circ Res. 1991; 68:856-69.
    • (1991) Circ Res , vol.68 , pp. 856-869
    • Olivetti, G.1    Capasso, J.M.2    Meggs, L.G.3
  • 49
    • 0022536391 scopus 로고
    • Left ventricular remodeling after myocardial infarction: A corollary to infarct expansion
    • McKay RG, Pfeffer MA, Pasternak RC et al. Left ventricular remodeling after myocardial infarction: a corollary to infarct expansion. Circulation. 1986; 74:693-702.
    • (1986) Circulation , vol.74 , pp. 693-702
    • McKay, R.G.1    Pfeffer, M.A.2    Pasternak, R.C.3
  • 50
    • 0029990688 scopus 로고    scopus 로고
    • The renin-angiotensin system in left ventricular remodeling
    • Blaufarb IS, Sonnenblick EH. The renin-angiotensin system in left ventricular remodeling. Am J Cardiol 1996; 77:8C-16C.
    • (1996) Am J Cardiol , vol.77
    • Blaufarb, I.S.1    Sonnenblick, E.H.2
  • 51
    • 13344259975 scopus 로고    scopus 로고
    • Ventricular remodeling
    • Maisch B. Ventricular remodeling. Cardiology. 1996; 87(suppl 1):2-10.
    • (1996) Cardiology , vol.87 , Issue.1 SUPPL. , pp. 2-10
    • Maisch, B.1
  • 52
    • 0028840484 scopus 로고
    • Effect of angiotensin II blockade on cardiac hypertrophy and remodeling: A review
    • Dalhof B. Effect of angiotensin II blockade on cardiac hypertrophy and remodeling: a review. J Hum Hypertens. 1995; 9(suppl 5):S37-44.
    • (1995) J Hum Hypertens , vol.9 , Issue.5 SUPPL.
    • Dalhof, B.1
  • 53
    • 0024221113 scopus 로고
    • Left ventricular hypertrophy. Epidemiological insights from the Framingham Heart Study
    • Levy D. Left ventricular hypertrophy. Epidemiological insights from the Framingham Heart Study. Drugs. 1988; 35(suppl 5):1-5.
    • (1988) Drugs , vol.35 , Issue.5 SUPPL. , pp. 1-5
    • Levy, D.1
  • 54
    • 0026517517 scopus 로고
    • Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies
    • Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens. 1992; 5:95-110.
    • (1992) Am J Hypertens , vol.5 , pp. 95-110
    • Dahlof, B.1    Pennert, K.2    Hansson, L.3
  • 55
    • 0031908811 scopus 로고    scopus 로고
    • Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996)
    • Schmieder RE, Schlaich MP, Klingbeil AU et al. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant. 1998; 13: 564-9.
    • (1998) Nephrol Dial Transplant , vol.13 , pp. 564-569
    • Schmieder, R.E.1    Schlaich, M.P.2    Klingbeil, A.U.3
  • 56
    • 0031721061 scopus 로고    scopus 로고
    • Regression of left ventricular hypertrophy in hypertension: Changing patterns with successive metaanalyses
    • Jennings G, Wong J. Regression of left ventricular hypertrophy in hypertension: changing patterns with successive metaanalyses. J Hypertens Suppl. 1998; 16:S29-34.
    • (1998) J Hypertens Suppl , vol.16
    • Jennings, G.1    Wong, J.2
  • 57
    • 0032983534 scopus 로고    scopus 로고
    • Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of heart failure caused by left ventricular systolic dysfunction
    • Sander G, McKinnie JJ, Greenberg SS et al. Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of heart failure caused by left ventricular systolic dysfunction. Prog Cardiovasc Dis. 1999; 41:265-300.
    • (1999) Prog Cardiovasc Dis , vol.41 , pp. 265-300
    • Sander, G.1    McKinnie, J.J.2    Greenberg, S.S.3
  • 58
    • 0023266532 scopus 로고
    • Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
    • CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987; 316:1429-35.
    • (1987) N Engl J Med , vol.316 , pp. 1429-1435
  • 59
    • 0025913812 scopus 로고
    • Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
    • SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991; 325:293-302.
    • (1991) N Engl J Med , vol.325 , pp. 293-302
  • 60
    • 0026785561 scopus 로고
    • Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
    • SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992; 327:685-91.
    • (1992) N Engl J Med , vol.327 , pp. 685-691
  • 61
    • 0028798758 scopus 로고
    • Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group
    • Crozier IG, Ikram H, Awan N et al. Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group. Circulation. 1995; 91:691-7.
    • (1995) Circulation , vol.91 , pp. 691-697
    • Crozier, I.G.1    Ikram, H.2    Awan, N.3
  • 62
    • 0027158296 scopus 로고
    • Systemic and coronary effects of the angiotensin II receptor antagonist EXP3174 in dogs
    • Richard V, Berdeaux A, Giudicelli JF. Systemic and coronary effects of the angiotensin II receptor antagonist EXP3174 in dogs. J Cardiovasc Pharmacol. 1993; 22:52-7.
    • (1993) J Cardiovasc Pharmacol , vol.22 , pp. 52-57
    • Richard, V.1    Berdeaux, A.2    Giudicelli, J.F.3
  • 63
    • 0027379394 scopus 로고
    • Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure
    • Gottlieb SS, Dickstein K, Fleck E et al. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation. 1993; 88:1602-9.
    • (1993) Circulation , vol.88 , pp. 1602-1609
    • Gottlieb, S.S.1    Dickstein, K.2    Fleck, E.3
  • 64
    • 0000472711 scopus 로고
    • Angiotensin II-mediated cardiac hypertrophy in adult rats
    • Abstract
    • Baker KM, Dostal DE, Chernin SC et al. Angiotensin II-mediated cardiac hypertrophy in adult rats. J Cell Biochem. 1991; 15C:167. Abstract.
    • (1991) J Cell Biochem , vol.15 C , pp. 167
    • Baker, K.M.1    Dostal, D.E.2    Chernin, S.C.3
  • 65
    • 4243965522 scopus 로고
    • Effects of the AT1 receptor antagonist losartan on angiotensin II induced hypertrophy of rat cardiomyocytes
    • Abstract
    • Murphy DD, Shepard J, Smith SC et al. Effects of the AT1 receptor antagonist losartan on angiotensin II induced hypertrophy of rat cardiomyocytes. FASEB J. 1992; 6:A1261. Abstract.
    • (1992) FASEB J , vol.6
    • Murphy, D.D.1    Shepard, J.2    Smith, S.C.3
  • 66
    • 0029102699 scopus 로고
    • Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure
    • Dickstein K, Chang P, Willenheimer R et al. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol. 1995; 26:438-45.
    • (1995) J Am Coll Cardiol , vol.26 , pp. 438-445
    • Dickstein, K.1    Chang, P.2    Willenheimer, R.3
  • 67
    • 0030881016 scopus 로고    scopus 로고
    • Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators
    • Lang RM, Elkayam U, Yellen LG et al. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators. J Am Coll Cardiol. 1997; 30:983-91.
    • (1997) J Am Coll Cardiol , vol.30 , pp. 983-991
    • Lang, R.M.1    Elkayam, U.2    Yellen, L.G.3
  • 68
    • 0001545029 scopus 로고    scopus 로고
    • Irbesartan compared with lisinopril in patients with mild to moderate heart failure
    • Abstract
    • Vijay N, Alhaddad IA, Marty DD et al. Irbesartan compared with lisinopril in patients with mild to moderate heart failure. J Am Coll Cardiol. 1998; 31(suppl A):68A. Abstract.
    • (1998) J Am Coll Cardiol , vol.31 , Issue.SUPPL. A
    • Vijay, N.1    Alhaddad, I.A.2    Marty, D.D.3
  • 69
    • 0034612118 scopus 로고    scopus 로고
    • Effect of losartan compared with captoptril on mortality in patients with symptomatic heart failure: Randomised trial - The Losartan Heart Failure Survival Study Elite II
    • Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captoptril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study Elite II. Lancet. 2000; 355:1582-7.
    • (2000) Lancet , vol.355 , pp. 1582-1587
    • Pitt, B.1    Poole-Wilson, P.A.2    Segal, R.3
  • 70
    • 0034074905 scopus 로고    scopus 로고
    • Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin converting enzyme inhibitors
    • Granger C, Ertl G, Kuch J et al. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin converting enzyme inhibitors. Am Heart J. 2000; 139:609-17.
    • (2000) Am Heart J , vol.139 , pp. 609-617
    • Granger, C.1    Ertl, G.2    Kuch, J.3
  • 71
    • 0031028695 scopus 로고    scopus 로고
    • Enalapril and losartan reduced cardiac mass and improved coronary hemodynamics in SHR
    • Nunez E, Hosoya K, Susic D et al. Enalapril and losartan reduced cardiac mass and improved coronary hemodynamics in SHR. Hypertension. 1997; 29:519-24.
    • (1997) Hypertension , vol.29 , pp. 519-524
    • Nunez, E.1    Hosoya, K.2    Susic, D.3
  • 72
    • 0031934185 scopus 로고    scopus 로고
    • Additive effects of enalapril and losartan in (mREN-2)27 transgenic rats
    • Richer C, Bruneval P, Menard J et al. Additive effects of enalapril and losartan in (mREN-2)27 transgenic rats. Hypertension. 1998; 31:692-8.
    • (1998) Hypertension , vol.31 , pp. 692-698
    • Richer, C.1    Bruneval, P.2    Menard, J.3
  • 73
    • 0029083653 scopus 로고
    • Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives
    • Azizi M, Chatellier G, Guyene TT et al. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation. 1995; 92:825-34.
    • (1995) Circulation , vol.92 , pp. 825-834
    • Azizi, M.1    Chatellier, G.2    Guyene, T.T.3
  • 74
    • 0031028895 scopus 로고    scopus 로고
    • Additive effects of losartan and enalapril on blood pressure and plasma active renin
    • Azizi M, Guyene TT, Chatellier G et al. Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension. 1997; 29:634-40.
    • (1997) Hypertension , vol.29 , pp. 634-640
    • Azizi, M.1    Guyene, T.T.2    Chatellier, G.3
  • 75
    • 0031781441 scopus 로고    scopus 로고
    • Safety, tolerability, and neurohormonal changes of the combination of captopril plus losartan in the early postinfarction period: A pilot study
    • Di Pasquale P, Bucca V, Scalzo S et al. Safety, tolerability, and neurohormonal changes of the combination of captopril plus losartan in the early postinfarction period: a pilot study. Cardiovasc Drugs Ther. 1998; 12:211-6.
    • (1998) Cardiovasc Drugs Ther , vol.12 , pp. 211-216
    • Di Pasquale, P.1    Bucca, V.2    Scalzo, S.3
  • 76
    • 0000465226 scopus 로고    scopus 로고
    • Combined treatment with losartan and enalapril vs enalapril on neurohormonal activation in patients with heart failure
    • Abstract
    • Pitt B, Dickstein K, Benedict C et al. Combined treatment with losartan and enalapril vs enalapril on neurohormonal activation in patients with heart failure. Circulation. 1996; 94:1-428. Abstract.
    • (1996) Circulation , vol.94 , pp. 1-428
    • Pitt, B.1    Dickstein, K.2    Benedict, C.3
  • 77
    • 0030658003 scopus 로고    scopus 로고
    • Angiotensin II-receptor blockade further reduces afterload safely in patients maximally treated with angiotensin-converting enzyme inhibitors for heart failure
    • Hamroff G, Blaufarb I, Mancini D et al. Angiotensin II-receptor blockade further reduces afterload safely in patients maximally treated with angiotensin-converting enzyme inhibitors for heart failure. J Cardiovasc Pharmacol. 1997; 30:533-6.
    • (1997) J Cardiovasc Pharmacol , vol.30 , pp. 533-536
    • Hamroff, G.1    Blaufarb, I.2    Mancini, D.3
  • 78
    • 0000465227 scopus 로고    scopus 로고
    • Hemodynamic response to AT1 receptor blockade with valsartan in ACE inhibitor-treated patients with heart failure. Valsartan Study Group
    • Abstract
    • Baruch L, Anand IS, Judd DL et al. Hemodynamic response to AT1 receptor blockade with valsartan in ACE inhibitor-treated patients with heart failure. Valsartan Study Group. Circulation. 1996; 94(suppl 1):I-428. Abstract.
    • (1996) Circulation , vol.94 , Issue.1 SUPPL.
    • Baruch, L.1    Anand, I.S.2    Judd, D.L.3
  • 79
    • 0000830642 scopus 로고    scopus 로고
    • Angiotensin II receptor blockade combined to ACE inhibition improves left ventricular dilation and exercise ejection fraction in congestive heart failure
    • Abstract
    • Tocchi M, Rosanio S, Anzuini A et al. Angiotensin II receptor blockade combined to ACE inhibition improves left ventricular dilation and exercise ejection fraction in congestive heart failure. J Am Coll Cardiol. 1998; 31(suppl A):188A. Abstract.
    • (1998) J Am Coll Cardiol , vol.31 , Issue.SUPPL. A
    • Tocchi, M.1    Rosanio, S.2    Anzuini, A.3
  • 80
    • 0001545027 scopus 로고    scopus 로고
    • Irbesartan combined with conventional therapy, including angiotensin converting enzyme inhibitors, in heart failure. Irbesartan Heart Failure Group
    • Abstract
    • Tonkon M, Awan N, Niazi I et al. Irbesartan combined with conventional therapy, including angiotensin converting enzyme inhibitors, in heart failure. Irbesartan Heart Failure Group. J Am Coll Cardiol. 1998; 31(suppl A):188A. Abstract.
    • (1998) J Am Coll Cardiol , vol.31 , Issue.SUPPL. A
    • Tonkon, M.1    Awan, N.2    Niazi, I.3
  • 81
    • 4244148359 scopus 로고    scopus 로고
    • Clinical benefits of long-term angiotensin II receptor blockade in patients with severe symptoms of congestive heart failure despite full angiotensin-converting enzyme inhibition
    • Abstract
    • Hamroff G, Blaufarb I, Mancini D et al. Clinical benefits of long-term angiotensin II receptor blockade in patients with severe symptoms of congestive heart failure despite full angiotensin-converting enzyme inhibition. J Am Coll Cardiol. 1998; 31(suppl A):188A. Abstract.
    • (1998) J Am Coll Cardiol , vol.31 , Issue.SUPPL. A
    • Hamroff, G.1    Blaufarb, I.2    Mancini, D.3
  • 82
    • 0033533456 scopus 로고    scopus 로고
    • Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. the RESOLVD Pilot Study Investigators
    • McKelvie RS, Yusuf S, Pericak D et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation. 1999; 100:1056-64.
    • (1999) Circulation , vol.100 , pp. 1056-1064
    • McKelvie, R.S.1    Yusuf, S.2    Pericak, D.3
  • 83
    • 0002839619 scopus 로고    scopus 로고
    • The Valsartan Heart Failure Trial (Val-HeFT)
    • Paper presented New Orleans, LA; Nov
    • Cohn JN. The Valsartan Heart Failure Trial (Val-HeFT). Paper presented at American Heart Association Scientific Sessions 2000. New Orleans, LA; Nov 2000.
    • (2000) American Heart Association Scientific Sessions 2000
    • Cohn, J.N.1
  • 84
    • 0026786643 scopus 로고
    • Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. The SAVE Investigators
    • Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. The SAVE Investigators. N Engl J Med. 1992; 327:669-77.
    • (1992) N Engl J Med , vol.327 , pp. 669-677
    • Pfeffer, M.A.1    Braunwald, E.2    Moye, L.A.3
  • 85
    • 0028273258 scopus 로고
    • GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction
    • Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet. 1994; 343:1115-22.
    • (1994) Lancet , vol.343 , pp. 1115-1122
  • 86
    • 0028862783 scopus 로고
    • Discovery of losartan, the first angiotensin II receptor antagonist
    • Timmermans PB, Duncia JV, Carini DJ et al. Discovery of losartan, the first angiotensin II receptor antagonist. J Hum Hypertens. 1995; 9(suppl 5):S3-18.
    • (1995) J Hum Hypertens , vol.9 , Issue.5 SUPPL.
    • Timmermans, P.B.1    Duncia, J.V.2    Carini, D.J.3
  • 87
    • 0025028032 scopus 로고
    • Prostaglandins, angiotensin II, and proteinuria
    • Dunn MJ. Prostaglandins, angiotensin II, and proteinuria. Nephron. 1990; 55(suppl 1):30-7.
    • (1990) Nephron , vol.55 , Issue.1 SUPPL. , pp. 30-37
    • Dunn, M.J.1
  • 88
    • 0027522956 scopus 로고
    • Angiotensin-converting enzyme inhibitors in diabetic nephropathy
    • Melchoir WR, Bindlish V, Jaber LA. Angiotensin-converting enzyme inhibitors in diabetic nephropathy. Ann Pharmacother. 1993; 27:344-50.
    • (1993) Ann Pharmacother , vol.27 , pp. 344-350
    • Melchoir, W.R.1    Bindlish, V.2    Jaber, L.A.3
  • 89
    • 0028960065 scopus 로고
    • Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects
    • Burnier M, Hagman M, Nussberger J et al. Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension. 1995; 25:602-9.
    • (1995) Hypertension , vol.25 , pp. 602-609
    • Burnier, M.1    Hagman, M.2    Nussberger, J.3
  • 90
    • 0027972824 scopus 로고
    • Angiotensin II receptor antagonists versus angiotensin converting enzyme inhibitors: Effects on renal function
    • Jover B, Mimran A. Angiotensin II receptor antagonists versus angiotensin converting enzyme inhibitors: effects on renal function. J Hypertens Suppl. 1994; 12:S3-9.
    • (1994) J Hypertens Suppl , vol.12
    • Jover, B.1    Mimran, A.2
  • 91
    • 0029069447 scopus 로고
    • Prevention and treatment of the complications of diabetes mellitus
    • Clark CM Jr, Lee DA. Prevention and treatment of the complications of diabetes mellitus. N Engl J Med. 1995; 332: 1210-7.
    • (1995) N Engl J Med , vol.332 , pp. 1210-1217
    • Clark Jr., C.M.1    Lee, D.A.2
  • 92
    • 0029116325 scopus 로고
    • Prevention and treatment of diabetic nephropathy
    • Foote EF. Prevention and treatment of diabetic nephropathy. Am J Health Syst Pharm. 1995; 52:1781-92.
    • (1995) Am J Health Syst Pharm , vol.52 , pp. 1781-1792
    • Foote, E.F.1
  • 93
    • 0023175729 scopus 로고
    • Effect of antihypertensive treatment on kidney function in diabetic nephropathy
    • Parving HH, Andersen AR, Smidt UM et al. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. Br Med J. 1987; 294:1443-7.
    • (1987) Br Med J , vol.294 , pp. 1443-1447
    • Parving, H.H.1    Andersen, A.R.2    Smidt, U.M.3
  • 94
    • 0027160570 scopus 로고
    • Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy
    • Parving HH, Smidt UM, Hommel E et al. Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy. Am J Kidney Dis. 1993; 22:188-95.
    • (1993) Am J Kidney Dis , vol.22 , pp. 188-195
    • Parving, H.H.1    Smidt, U.M.2    Hommel, E.3
  • 95
    • 0028011891 scopus 로고
    • Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group
    • Viberti G, Mogensen CE, Groop LC et al. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA. 1994; 271:275-9.
    • (1994) JAMA , vol.271 , pp. 275-279
    • Viberti, G.1    Mogensen, C.E.2    Groop, L.C.3
  • 96
    • 0027517659 scopus 로고
    • The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group
    • Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993; 329:1456-62.
    • (1993) N Engl J Med , vol.329 , pp. 1456-1462
    • Lewis, E.J.1    Hunsicker, L.G.2    Bain, R.P.3
  • 97
    • 0026778853 scopus 로고
    • Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: One year analysis
    • Chan JCN, Cockram CS, Nicholls MG et al. Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: one year analysis. BMJ. 1992; 305:981-5.
    • (1992) BMJ , vol.305 , pp. 981-985
    • Jcn, C.1    Cockram, C.S.2    Nicholls, M.G.3
  • 98
    • 0027517013 scopus 로고
    • Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients
    • Ravid M, Savin H, Jutrin I et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med. 1993; 118:577-81.
    • (1993) Ann Intern Med , vol.118 , pp. 577-581
    • Ravid, M.1    Savin, H.2    Jutrin, I.3
  • 99
    • 0030056947 scopus 로고    scopus 로고
    • Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin dependent diabetes mellitus. A 7-year follow-up study
    • Ravid M, Lang R, Rachmani R et al. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med. 1996; 156:286-9.
    • (1996) Arch Intern Med , vol.156 , pp. 286-289
    • Ravid, M.1    Lang, R.2    Rachmani, R.3
  • 100
    • 0027049331 scopus 로고
    • Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis
    • Kasiske BL, Kalil RS, Ma JZ et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med. 1993; 118:129-38.
    • (1993) Ann Intern Med , vol.118 , pp. 129-138
    • Kasiske, B.L.1    Kalil, R.S.2    Ma, J.Z.3
  • 101
    • 0024324630 scopus 로고
    • Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril
    • Heeg JE, de John PE, van der Hem GK et al. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int. 1989; 36:272-9.
    • (1989) Kidney Int , vol.36 , pp. 272-279
    • Heeg, J.E.1    De John, P.E.2    Van Der Hem, G.K.3
  • 102
    • 0035165760 scopus 로고    scopus 로고
    • Clinical practice recommendations 2001. Diabetic nephropathy
    • American Diabetes Association. Clinical practice recommendations 2001. Diabetic nephropathy. Diabetes Care. 2001; 24(suppl 1):S69-72.
    • (2001) Diabetes Care , vol.24 , Issue.1 SUPPL.
  • 103
    • 0033852481 scopus 로고    scopus 로고
    • Preserving renal function in adults with hypertension and diabetes: A consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group
    • Bakris GL, Williams M, Dworkin L et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000; 36:646-61.
    • (2000) Am J Kidney Dis , vol.36 , pp. 646-661
    • Bakris, G.L.1    Williams, M.2    Dworkin, L.3
  • 104
    • 0026657559 scopus 로고
    • Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass
    • Lafayette RA, Mayer G, Park SK et al. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest. 1992; 90:766-71.
    • (1992) J Clin Invest , vol.90 , pp. 766-771
    • Lafayette, R.A.1    Mayer, G.2    Park, S.K.3
  • 105
    • 0031595541 scopus 로고    scopus 로고
    • Angiotensin AT1 receptor antagonism and protection against cardiovascular end-organ damage
    • Nishikawa K. Angiotensin AT1 receptor antagonism and protection against cardiovascular end-organ damage. J Hum Hypertens. 1998; 12:301-9.
    • (1998) J Hum Hypertens , vol.12 , pp. 301-309
    • Nishikawa, K.1
  • 106
    • 0027633488 scopus 로고
    • Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes
    • Remuzzi A, Perico N, Amuchastegui CS et al. Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol. 1993; 4:40-9.
    • (1993) J Am Soc Nephrol , vol.4 , pp. 40-49
    • Remuzzi, A.1    Perico, N.2    Amuchastegui, C.S.3
  • 107
    • 0031304268 scopus 로고    scopus 로고
    • Irbesartan lowers blood pressure and ameliorates renal injury in experimental non-insulin-dependent diabetes mellitus
    • O'Donnell MP, Crary GS, Oda H et al. Irbesartan lowers blood pressure and ameliorates renal injury in experimental non-insulin-dependent diabetes mellitus. Kidney Int Suppl. 1997; 63:S218-20.
    • (1997) Kidney Int Suppl , vol.63
    • O'Donnell, M.P.1    Crary, G.S.2    Oda, H.3
  • 108
    • 0028130636 scopus 로고
    • Contribution of renal angiotensin II type I receptor to gene expressions in hypertension-induced renal injury
    • Kim S, Ohta K, Hamaguchi A et al. Contribution of renal angiotensin II type I receptor to gene expressions in hypertension-induced renal injury. Kidney Int. 1994; 46:1346-58.
    • (1994) Kidney Int , vol.46 , pp. 1346-1358
    • Kim, S.1    Ohta, K.2    Hamaguchi, A.3
  • 109
    • 0031605321 scopus 로고    scopus 로고
    • Role of AT1 angiotensin II receptors in renal ischemic injury
    • Kontogiannis J, Burns KD. Role of AT1 angiotensin II receptors in renal ischemic injury. Am J Physiol. 1998; 274:F79-90.
    • (1998) Am J Physiol , vol.274
    • Kontogiannis, J.1    Burns, K.D.2
  • 110
    • 0031890736 scopus 로고    scopus 로고
    • Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation
    • Ots M, Mackenzie HS, Troy JL et al. Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. J Am Soc Nephrol. 1998; 9:224-30.
    • (1998) J Am Soc Nephrol , vol.9 , pp. 224-230
    • Ots, M.1    Mackenzie, H.S.2    Troy, J.L.3
  • 111
    • 0031049715 scopus 로고    scopus 로고
    • Modulation of plasminogen activator inhibitor-1 in vivo: A new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition
    • Oikawa T, Freeman M, Lo W et al. Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int. 1997; 51:164-72.
    • (1997) Kidney Int , vol.51 , pp. 164-172
    • Oikawa, T.1    Freeman, M.2    Lo, W.3
  • 112
    • 0028335425 scopus 로고
    • Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease
    • Gansevoort RT, de Zeeuw D, Shahinfar S et al. Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hypertens Suppl 1994; 12:S37-42.
    • (1994) J Hypertens Suppl , vol.12
    • Gansevoort, R.T.1    De Zeeuw, D.2    Shahinfar, S.3
  • 113
    • 0028295765 scopus 로고
    • Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system?
    • Gansevoort RT, de Zeeuw D, de Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int. 1994; 45:861-7.
    • (1994) Kidney Int , vol.45 , pp. 861-867
    • Gansevoort, R.T.1    De Zeeuw, D.2    De Jong, P.E.3
  • 114
    • 0030757514 scopus 로고    scopus 로고
    • Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study
    • Nielsen S, Dollerop J, Nielsen B et al. Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study. Nephrol Dial Transplant. 1997; 12(suppl 2):19-23.
    • (1997) Nephrol Dial Transplant , vol.12 , Issue.2 SUPPL. , pp. 19-23
    • Nielsen, S.1    Dollerop, J.2    Nielsen, B.3
  • 115
    • 0030658031 scopus 로고    scopus 로고
    • Long-term treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in mild hypertensives with type II diabetes
    • Trenkwalder P, Lehtovirta M, Dahl K. Long-term treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in mild hypertensives with type II diabetes. J Hum Hypertens. 1997; 11(suppl 2):S81-3.
    • (1997) J Hum Hypertens , vol.11 , Issue.2 SUPPL.
    • Trenkwalder, P.1    Lehtovirta, M.2    Dahl, K.3
  • 116
    • 0031424634 scopus 로고    scopus 로고
    • A long-term comparison between enalapril and captopril on insulin sensitivity in normotensive non-insulin dependent diabetic volunteers
    • Tillman HC, Walker RJ, Lewis-Barned NJ et al. A long-term comparison between enalapril and captopril on insulin sensitivity in normotensive non-insulin dependent diabetic volunteers. J Clin Pharm Ther. 1997; 22:273-8.
    • (1997) J Clin Pharm Ther , vol.22 , pp. 273-278
    • Tillman, H.C.1    Walker, R.J.2    Lewis-Barned, N.J.3
  • 117
    • 0034057595 scopus 로고    scopus 로고
    • Insulin sensitivity in hypertensive type 2 diabetic patients after 1 and 19 days' treatment with trandolapril
    • New JP, Bilous RW, Walker M. Insulin sensitivity in hypertensive type 2 diabetic patients after 1 and 19 days' treatment with trandolapril. Diabet Med. 2000; 17:134-40.
    • (2000) Diabet Med , vol.17 , pp. 134-140
    • New, J.P.1    Bilous, R.W.2    Walker, M.3
  • 118
    • 0031766034 scopus 로고    scopus 로고
    • Captopril does not improve insulin action in essential hypertension: A double-blind placebo-controlled study
    • Wiggam MI, Hunter SJ, Atkinson AB et al. Captopril does not improve insulin action in essential hypertension: a double-blind placebo-controlled study. J Hypertens. 1998; 16:1651-7.
    • (1998) J Hypertens , vol.16 , pp. 1651-1657
    • Wiggam, M.I.1    Hunter, S.J.2    Atkinson, A.B.3
  • 119
    • 0032810189 scopus 로고    scopus 로고
    • Insulin sensitivity in patients with essential hypertension: No influence of the ACE inhibitor enalapril
    • Heise T, Heinemann L, Kristahn K et al. Insulin sensitivity in patients with essential hypertension: no influence of the ACE inhibitor enalapril. Horm Metal Res. 1999; 31:418-23.
    • (1999) Horm Metal Res , vol.31 , pp. 418-423
    • Heise, T.1    Heinemann, L.2    Kristahn, K.3
  • 120
    • 0031763235 scopus 로고    scopus 로고
    • Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of nondiabetic hypertensive patients
    • Fogari R, Zoppi A, Corradi L et al. Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of nondiabetic hypertensive patients. Br J Clin Pharmacol. 1998; 46:467-71.
    • (1998) Br J Clin Pharmacol , vol.46 , pp. 467-471
    • Fogari, R.1    Zoppi, A.2    Corradi, L.3
  • 121
    • 0033056519 scopus 로고    scopus 로고
    • Effects of quinapril and losartan on insulin sensitivity in genetic hypertensive rats with different metabolic abnormalities
    • Nakagawa H, Daihara M, Tamakawa H et al. Effects of quinapril and losartan on insulin sensitivity in genetic hypertensive rats with different metabolic abnormalities. J Cardiovasc Pharmacol. 1999; 34: 28-33.
    • (1999) J Cardiovasc Pharmacol , vol.34 , pp. 28-33
    • Nakagawa, H.1    Daihara, M.2    Tamakawa, H.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.